The personalised vaccine has succeeded in a final-stage melanoma trial. Here’s how it works, when it could become available and why researchers hope the approach can be used against other cancers.

Moderna and Merck said their experimental mRNA cancer treatment met goals in a late-stage melanoma trial. The result reduced the risk of recurrence or spread versus Keytruda alone and lifted Moderna shares sharply.